 Study subjects will be treated with standard adjuvant hormonal therapy for a total of 5 years or until disease relapse or until HT is permanently discontinued for other reasons. The choice of endocrine treatment strategy drugs to be used or their sequence, if the sequential option has been decided is left at the discretion of the participating site. Adjuvant HT will commence after the completion of adjuvant chemotherapy andor radiotherapy. Percentage change from baseline of the blood coagulation parameters at 6, 12, 18, and 24 months of treatment. The blood coagulation parameters which will be measured are fibrinogen, prothrombin time PT and activated partial thromboplastin time aPTT. 